Duchenne muscular dystrophy is initiated by dystrophin loss but is accompanied by profound metabolic remodelling. Here, we identify suppression of the muscle-enriched adenylosuccinate synthase, ADSS1, and the purine nucleotide cycle in mdx muscle. Integrated multi-omic profiling revealed a compensated purine-stress state in which nucleotide salvage and quality control were increased to preserve adenine nucleotide abundance and buffer consequential toxic/disruptive deoxy-/nucleotide production. Purine metabolism was the highest-impact joint pathway with metabolite and transcript hits in mdx muscle, and its maintenance program was directionally conserved in human ADSS1 myopathy. Interventions positioned around ADSS1 separated the outputs of this node. Ribose and dimethyl fumarate remodelled upstream or downstream stress programs, whereas only adenylosuccinic acid bypassed ADSS1 to expand the adenine nucleotide pool and remodel CoA/acetyl-CoA metabolism. All three interventions suppressed pro-adipogenic transcription without broadly correcting the lipidome. These findings identify ADSS1 as a regulated metabolic control node that couples purine retention to inflammatory and adipogenic remodelling in dystrophic muscle.
Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by loss of dystrophin. Utrophin, a structural and functional paralogue of dystrophin, can compensate for dystrophin deficiency and represents a therapeutic target applicable to patients irrespective of their DMD mutation. However, utr...
S. Guiraud, B. Edwards, S. Squire et al.· bioRxiv· 0 citations
The core pathogenic role of the LCN2‐MMP9‐ECM‐FAK axis in GC‐induced muscle atrophy is revealed, providing a promising novel therapeutic target for steroid myopathy.
Hongwei Shi, Xiaojing Hao, Yi Yan et al.· Advancement of science· 0 citations
This review critically examines the molecular and spatial architecture of glucose metabolism in the parkinsonian brain and evaluates the therapeutic potential of emerging metabolic modulators, including terazosin, cordycepin, and GLP-1 receptor agonists.
Ying Yi, Cen Chen, You He et al.· Medicinal research reviews (...· 0 citations
It is shown that antisense oligonucleotide-mediated inhibition of miR-128-3p restores muscle mass and function in aged mice, improves cardiac function while limiting adverse remodeling following myocardial infarction, and ameliorates skeletal and cardiac muscle pathology in mouse and pig models of Duchenne muscular dys...
Melissa A. Boldridge, Lei Xu, Xiao-Yin Wang et al.· bioRxiv· 0 citations
It is shown that fatty acid synthase (FASN), the rate-limiting enzyme of de novo lipogenesis, is upregulated in cardiomyocytes of ACM patients and of a cardiomyocyte-specific Dsg2-mutant mouse model, identifying FASN as a candidate therapeutic target in ACM.
Zi-Rui Liu, Hao Cui, Tian-Shuo Yang et al.· iScience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.